Patient-Reported Outcome Response and Safety Profile in Patients With Moderately to Severely Active Rheumatoid Arthritis Treated With Baricitinib 2-mg

被引：1
|
作者：
Sholter, Dalton [1 ]
Wu, Jianmin [2 ]
Jia, Bochao [2 ]
Zhang, Hong [3 ]
Griffing, Kirstin [2 ]
Quebe, Amanda [2 ]
Birt, Julie [2 ]
Reis, Paulo [2 ]
Liu, Huaxiang [4 ]
Bingham, Clifton [5 ]
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] TechData Serv, Prussia, PA USA
[4] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[5] Johns Hopkins Arthrit Ctr, Baltimore, MD USA
来源：
JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
7
引用
收藏
页码：1109 / 1110
页数：2
相关论文
共 50 条
  • [1] Rapid Clinical Response in Patients with Moderately to Severely Active Rheumatoid Arthritis Treated with Baricitinib
    Sholter, Dalton
    Wu, Jianmin
    Wang, Duzhe
    Quebe, Amanda
    Griffing, Kirstin
    Bykerk, Vivian
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 834 - 834
  • [2] SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS
    Genovese, M.
    Smolen, J.
    Takeuchi, T.
    Hyslop, D.
    MacIas, W.
    Rooney, T.
    Chen, L.
    Dickson, C.
    Riddle, J.
    Cardillo, T.
    Winthrop, K.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 31 - 31
  • [3] SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS
    Genovese, M.
    Smolen, J.
    Takeuchi, T.
    Hyslop, D.
    MacIas, W.
    Rooney, T.
    Chen, L.
    Dickson, C.
    Riddle, J.
    Cardillo, T.
    Winthrop, K.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 28 - 28
  • [4] Patient Disease Trajectories in Baricitinib-2mg-treated Patients with Rheumatoid Arthritis and Inadequate Response to csDMARDs
    Pope, Janet
    Li, Zhanguo
    Genovese, Mark
    Otawa, Susan
    Sun, Luna
    Chandran, Shelly
    Keystone, Edward
    Dougados, Maxime
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1127 - 1128
  • [5] PATIENT-REPORTED OUTCOMES AMONG TREATED RHEUMATOID ARTHRITIS PATIENTS
    Feinberg, B. A.
    Olson, T.
    Burruss, R. A.
    Garofalo, D. F.
    VALUE IN HEALTH, 2016, 19 (03) : A237 - A237
  • [6] Patient Disease Trajectories in Baricitinib 2-mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
    Genovese, Mark
    Weinblatt, Michael
    Wu, Jianmin
    Jia, Bochao
    Quebe, Amanda
    Sun, Luna
    Chen, Yun-Fei
    Helt, Cameron
    Griffing, Kirstin
    Reis, Paulo
    Pope, Janet
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1129 - 1129
  • [7] Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
    Smolen, Josef S.
    Genovese, Mark C.
    Takeuchi, Tsutomu
    Hyslop, David L.
    Macias, William L.
    Rooney, Terence
    Chen, Lei
    Dickson, Christina L.
    Camp, Jennifer Riddle
    Cardillo, Tracy E.
    Ishii, Taeko
    Winthrop, Kevin L.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (01) : 7 - 18
  • [8] Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
    Dasgupta, B.
    Bertin, P.
    Settas, L.
    Fonseca, J. E.
    Wolff, V.
    Yao, R.
    Govoni, M.
    Vastesaeger, N.
    Weng, H. H.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S209 - S209
  • [9] Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
    Genovese, Mark
    Weinblatt, Michael
    Wu, Jianmin
    Jia, Bochao
    Quebe, Amanda
    Sun, Luna
    Chen, Yun-Fei
    Helt, Cameron
    Bacani, A. Kirstin
    Reis, Paulo
    Pope, Janet
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [10] UPADACITINIB MONOTHERAPY IMPROVES PATIENT-REPORTED OUTCOMES IN METHOTREXATE-NAIVE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM SELECT-EARLY
    Strand, Vibeke
    Tundia, Namita
    Radominski, Sebastiao
    Friedman, Alan
    Dunlap, Kendall
    Goldschmidt, Deborah
    Bergman, Martin
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 372 - 373
12345